AZN AstraZeneca PLC

TIDMAZN

RNS Number : 9938W

AstraZeneca PLC

03 May 2016

ASTRAZENECA COMPLETES ACQUISITION

OF TAKEDA'S RESPIRATORY BUSINESS

AstraZeneca today announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

 
 Media Enquiries 
                                               +44 20 7604 
 Neil Burrows           UK/Global               8032 
                                               +44 20 7604 
 Vanessa Rhodes         UK/Global               8037 
                                               +44 20 7604 
 Karen Birmingham       UK/Global               8120 
                                               +46 8 553 260 
 Jacob Lund             Sweden                  20 
 Abigail Bozarth        US                     +1 302 885 2677 
 Investor Enquiries 
 UK 
 Thomas Kudsk Larsen                           +44 7818 524185 
 Eugenia Litz           RIA                    +44 7884 735627 
 Nick Stone             CVMD                   +44 7717 618834 
 Craig Marks            Finance                +44 7881 615764 
 Christer Gruvris       Consensus Forecasts    +44 7827 836825 
 US 
 Lindsey Trickett        Oncology, ING         +1 240 543 7970 
 Mitch Chan              Oncology              +1 240 477 3771 
 Dial / Toll-Free                              +1 866 381 7277 
 

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

03 May 2016

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUOUVRNAAVRRR

(END) Dow Jones Newswires

May 03, 2016 02:16 ET (06:16 GMT)

AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024

AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024